The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 19, Issue 8, Pages 2337
Publisher
MDPI AG
Online
2018-08-09
DOI
10.3390/ijms19082337
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma
- (2018) Hengyu Zhou et al. CELL PROLIFERATION
- Recent advances in the discovery of potent and selective HDAC6 inhibitors
- (2018) Xiu-Xiu Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma
- (2018) Zebing Liu et al. JOURNAL OF PATHOLOGY
- Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors
- (2018) Jooeun Bae et al. LEUKEMIA
- Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
- (2017) Ana-Alicia López-Iglesias et al. Journal of Hematology & Oncology
- Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
- (2017) A Ray et al. LEUKEMIA
- The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
- (2017) L Besse et al. Blood Cancer Journal
- HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer
- (2017) Zhixiong Dong et al. Oncotarget
- HDAC4 is expressed on multiple T cell lineages but dispensable for their development and function
- (2017) Queping Liu et al. Oncotarget
- Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
- (2017) Claudia A. Simões-Pires et al. Jove-Journal of Visualized Experiments
- Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor
- (2017) Brian J. North et al. PLoS One
- Abstract 3996: KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110β/p110δ and HDAC6 with single-agent and combination activity
- (2016) Stephen J. Shuttleworth CANCER RESEARCH
- Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib
- (2016) Jennifer E. Amengual et al. CLINICAL CANCER RESEARCH
- Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides
- (2016) Francine Foss et al. Clinical Lymphoma Myeloma & Leukemia
- Histone deacetylase inhibitors in multiple myeloma: from bench to bedside
- (2016) Takeshi Harada et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- In vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development
- (2016) Alba Azagra et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
- (2016) Andrew J Yee et al. LANCET ONCOLOGY
- Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma
- (2016) Teru Hideshima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models
- (2016) Pengyu Huang et al. Oncotarget
- The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101
- (2015) Thomas Mehrling et al. Anti-Cancer Agents in Medicinal Chemistry
- Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
- (2015) Yuko Mishima et al. BRITISH JOURNAL OF HAEMATOLOGY
- FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
- (2015) H.-Z. Lee et al. CLINICAL CANCER RESEARCH
- Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
- (2015) J. E. Amengual et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase 3 Is Required for T Cell Maturation
- (2015) Fan-Chi Hsu et al. JOURNAL OF IMMUNOLOGY
- Analysis of class I and II histone deacetylase gene expression in human leukemia
- (2015) Hui Yang et al. LEUKEMIA & LYMPHOMA
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
- (2015) T Hideshima et al. Blood Cancer Journal
- Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
- (2015) Afua Adjeiwaa Mensah et al. Oncotarget
- Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2
- (2015) Lu Gao et al. Biomed Research International
- HDAC6 Deacetylates Ku70 and Regulates Ku70-Bax Binding in Neuroblastoma
- (2015) Chitra Subramanian et al. NEOPLASIA
- Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
- (2014) Ning Ding et al. Cancer Cell International
- Selective class IIa HDAC inhibitors: myth or reality
- (2014) Eros Di Giorgio et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells
- (2014) G. Dasmahapatra et al. MOLECULAR CANCER THERAPEUTICS
- The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
- (2014) Shalome Bassett et al. Nutrients
- The emerging role of acetylation in the regulation of autophagy
- (2013) Ágnes Bánréti et al. Autophagy
- LC3B-II deacetylation by histone deacetylase 6 is involved in serum-starvation-induced autophagic degradation
- (2013) Kun-Peng Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts
- (2013) Richard D.W. Kelly et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice
- (2013) O. M. Dovey et al. BLOOD
- Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC
- (2013) Sridurga Mithraprabhu et al. BRITISH JOURNAL OF HAEMATOLOGY
- A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas
- (2013) Tint Lwin et al. JOURNAL OF CLINICAL INVESTIGATION
- Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors
- (2013) T Hideshima et al. LEUKEMIA
- Oncogenic Shp2 disturbs microtubule regulation to cause HDAC6-dependent ERK hyperactivation
- (2013) S-C Tien et al. ONCOGENE
- Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
- (2013) G M Matthews et al. Cell Death & Disease
- Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma
- (2012) Miryoung Kim et al. ANNALS OF PHARMACOTHERAPY
- Development and therapeutic impact of HDAC6-selective inhibitors
- (2012) Sabrina Dallavalle et al. BIOCHEMICAL PHARMACOLOGY
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Abstract 2741: Synergistic inhibition of tumor growth and overcoming chemo-resistance by simultaneously targeting key components in DNA damage/repair, epigenetic, and putative cancer stem cell signaling pathways using novel dual-functional DNA-alkylating/HDAC inhibitor and tumor suppressor gene nanoparticles in lung cancer
- (2012) Shaoyu Yan et al. CANCER RESEARCH
- Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis
- (2012) E Kerr et al. CELL DEATH AND DIFFERENTIATION
- Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy
- (2012) T. Ai et al. CURRENT MEDICINAL CHEMISTRY
- Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
- (2012) Praveer Gupta et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone Deacetylase in Chronic Lymphocytic Leukemia
- (2012) J.C. Wang et al. ONCOLOGY
- miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E -miR-155 transgenic mouse model
- (2012) S. K. Sandhu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Histone Deacetylases 6 and 9 and Sirtuin-1 Control Foxp3+ Regulatory T Cell Function Through Shared and Isoform-Specific Mechanisms
- (2012) U. H. Beier et al. Science Signaling
- Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
- (2012) Androniki Kretsovali et al. Stem Cells International
- Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
- (2011) M. J. Bishton et al. BLOOD
- Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
- (2011) R Pili et al. BRITISH JOURNAL OF CANCER
- HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
- (2011) Omar Khan et al. IMMUNOLOGY AND CELL BIOLOGY
- Interplay between histone deacetylases and autophagy - from cancer therapy to neurodegeneration
- (2011) Oliver Trüe et al. IMMUNOLOGY AND CELL BIOLOGY
- Protein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C Termini
- (2011) Hui Ouyang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
- (2011) Claudia P. Miller et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes
- (2011) Maria N Navarro et al. NATURE IMMUNOLOGY
- Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
- (2011) Valentina Zuco et al. PLoS One
- Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy
- (2010) Ali R. Jazirehi ANTI-CANCER DRUGS
- Proteasome and HDAC: who's zooming who?
- (2010) D. McConkey BLOOD
- The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
- (2010) G. Dasmahapatra et al. BLOOD
- Valproic Acid in the Complex Therapy of Malignant Tumors
- (2010) J. Hrebackova et al. CURRENT DRUG TARGETS
- Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
- (2010) Helen J. Mackay et al. EUROPEAN JOURNAL OF CANCER
- Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma
- (2010) Heiner Adams et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Nonhistone protein acetylation as cancer therapy targets
- (2010) Brahma N Singh et al. Expert Review of Anticancer Therapy
- HDACi - going through the mechanisms
- (2010) Malgorzata Wanczyk Frontiers in Bioscience-Landmark
- Targeting histone deacetyalses in the treatment of B- and T-cell malignancies
- (2010) Jasmine Zain et al. INVESTIGATIONAL NEW DRUGS
- The Role of HDAC6 in Cancer
- (2010) Grace I. Aldana-Masangkay et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
- (2010) Ya-Li Yao et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Conditional Deletion of Histone Deacetylase 1 in T Cells Leads to Enhanced Airway Inflammation and Increased Th2 Cytokine Production
- (2010) R. Grausenburger et al. JOURNAL OF IMMUNOLOGY
- Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
- (2010) Kyle V. Butler et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Histone deacetylases and epigenetic therapies of hematological malignancies
- (2010) Ciro Mercurio et al. PHARMACOLOGICAL RESEARCH
- Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents
- (2010) M. Namdar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors
- (2009) Annunziata Gloghini et al. BRITISH JOURNAL OF HAEMATOLOGY
- Epigenetics in cancer
- (2009) S. Sharma et al. CARCINOGENESIS
- Epigenetic Modifiers: Basic Understanding and Clinical Development
- (2009) R. L. Piekarz et al. CLINICAL CANCER RESEARCH
- Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
- (2009) D. S. Schrump CLINICAL CANCER RESEARCH
- Clinical Studies of Histone Deacetylase Inhibitors
- (2009) H. M. Prince et al. CLINICAL CANCER RESEARCH
- Inhibition of HDAC9 Increases T Regulatory Cell Function and Prevents Colitis in Mice
- (2009) Edwin F. de Zoeten et al. GASTROENTEROLOGY
- Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas
- (2009) Lena Marquard et al. HISTOPATHOLOGY
- Tubacin Kills Epstein-Barr Virus (EBV)-Burkitt Lymphoma Cells by Inducing Reactive Oxygen Species and EBV Lymphoblastoid Cells by Inducing Apoptosis
- (2009) Junichi Kawada et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Protein Kinase A-regulated Assembly of a MEF2·HDAC4 Repressor Complex Controls c-Jun Expression in Vascular Smooth Muscle Cells
- (2009) Joseph W. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Histone deacetylase inhibitors: Potential in cancer therapy
- (2009) P.A. Marks et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6
- (2009) In Ah Kim et al. RADIOTHERAPY AND ONCOLOGY
- Inhibition of histone deacetylase1 induces autophagy
- (2008) Meeyeon Oh et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
- (2008) R. Rao et al. BLOOD
- Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells
- (2008) W. Fiskus et al. BLOOD
- The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
- (2008) Y.-S. Lee et al. CANCER RESEARCH
- Role of the Aggresome Pathway in Cancer: Targeting Histone Deacetylase 6-Dependent Protein Degradation
- (2008) A. Rodriguez-Gonzalez et al. CANCER RESEARCH
- Myc-Mediated Transcriptional Repression by Recruitment of Histone Deacetylase
- (2008) J. F. Kurland et al. CANCER RESEARCH
- Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
- (2008) Simone Fulda CURRENT CANCER DRUG TARGETS
- Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors
- (2008) Sabrina Dallavalle et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- p21 and p27: roles in carcinogenesis and drug resistance
- (2008) Abde M. Abukhdeir et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
- (2008) L Marquard et al. HISTOPATHOLOGY
- The aggresome pathway as a target for therapy in hematologic malignancies
- (2008) Tiffany Simms-Waldrip et al. MOLECULAR GENETICS AND METABOLISM
- The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance
- (2008) Alejandro Villagra et al. NATURE IMMUNOLOGY
- The many roles of histone deacetylases in development and physiology: implications for disease and therapy
- (2008) Michael Haberland et al. NATURE REVIEWS GENETICS
- HDAC6: a key regulator of cytoskeleton, cell migration and cell–cell interactions
- (2008) Agustín Valenzuela-Fernández et al. TRENDS IN CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started